Krystal Biotech (KRYS) Projected to Post Quarterly Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) is expected to be releasing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Krystal Biotech to post earnings of $1.04 per share and revenue of $93.7230 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, November 3, 2025 at 8:30 AM ET.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The company had revenue of $96.04 million for the quarter, compared to analysts’ expectations of $95.42 million. On average, analysts expect Krystal Biotech to post $6 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Krystal Biotech Stock Up 4.5%

Shares of KRYS stock opened at $197.51 on Friday. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $207.84. The firm has a fifty day moving average of $169.37 and a 200-day moving average of $152.91. The firm has a market capitalization of $5.72 billion, a price-to-earnings ratio of 40.14 and a beta of 0.64.

Institutional Trading of Krystal Biotech

Institutional investors and hedge funds have recently bought and sold shares of the stock. Osaic Holdings Inc. raised its holdings in shares of Krystal Biotech by 41.4% in the 2nd quarter. Osaic Holdings Inc. now owns 393 shares of the company’s stock valued at $54,000 after purchasing an additional 115 shares during the period. Empowered Funds LLC acquired a new position in Krystal Biotech during the first quarter worth approximately $218,000. Royal Bank of Canada raised its stake in Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after buying an additional 964 shares during the period. EP Wealth Advisors LLC raised its stake in Krystal Biotech by 4.0% in the second quarter. EP Wealth Advisors LLC now owns 2,726 shares of the company’s stock valued at $375,000 after buying an additional 105 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in shares of Krystal Biotech by 310.7% in the second quarter. Tower Research Capital LLC TRC now owns 2,998 shares of the company’s stock valued at $412,000 after buying an additional 2,268 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on KRYS shares. Bank of America increased their price target on Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Guggenheim set a $224.00 price target on shares of Krystal Biotech and gave the company a “buy” rating in a research note on Friday, October 17th. HC Wainwright reissued a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Monday, September 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Krystal Biotech in a research report on Wednesday, October 8th. Finally, Chardan Capital lowered their target price on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a report on Friday, August 22nd. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $223.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).